Reimagining Medicine

Company overview Financial review Conclusions Appendix References Strong business momentum as we become a focused medicines company Very strong H1 sales growth, robust margin expansion: Broad-based performance across core therapeutic areas and key geographies Confidence in near and mid-term growth: Including rich pipeline, Kisqali®, PluvictoⓇ and iptacopan Raising 2023 FY guidance Initiating up-to USD 15 billion share buyback On track for Sandoz spin-off in early Q4 2023 28 Investor Relations | Q2 2023 Results NOVARTIS | Reimagining Medicine

View entire presentation